Scottsdale, AZ (PRWEB) June 27, 2011
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Multiple Sclerosis,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area.
In the wake of Merck Serono’s decision to withdraw its MS application for cladribine and pull the therapy from markets where it is approved, Novartis’ Gilenya (fingolimod) is poised to dominate this market as the only approved oral therapy, at least for now.
During in-depth interviews with global neurology thought leaders, discussion focused on the following topics:
- Likely reasons for the inability of Merck Serono to obtain regulatory approvals in the US and Europe for cladribine.
- Early perceptions of Gilenya and barriers to accelerating prescribing.
- Biogen’s new BG-12 data, which panelists view as “too good to be true.”
- Teva’s laquinimod data, which appears to be “too bad to be true.”
- The potential for a JC virus diagnostic to save Tysabri.
- Very strong ocrelizumab results.
- And much more.
Transcripts of six qualitative interviews with neurologists are included in the report.
Companies discussed in this report: Abbott, Acorda, Bayer, Biogen Idec, Boehringer Ingelheim, Coronado, Elan, Exelixis, Genmab, Genentech, GlaxoSmithKline, Kyorin, Merck Serono, Novartis, Ono, Pfizer, PDL, Roche, Sanofi-Aventis, Teva.
The full report may be purchased by contacting MedPredict.
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.
For more information contact: